Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection

PLoS Pathogens

Volumn 13, Issue 5, 2017, Pages

  Iampietro, Mathieu ^a,b   Younan, Patrick ^a,b   Nishida, Andrew ^c   Dutta, Mukta ^c   Lubaki, Ndongala Michel ^a,b   Santos, Rodrigo I ^a,b   Koup, Richard A ^d   Katze, Michael G ^c,e   Bukreyev, Alexander ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Washington National Primate Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; INTERLEUKIN 7; STAPHYLOCOCCUS ENTEROTOXIN B; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; PROTEIN BINDING; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; VIRUS ENVELOPE PROTEIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; CONFOCAL MICROSCOPY; EBOLAVIRUS; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INNATE IMMUNITY; LYMPHOCYTOPENIA; NECROSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; EBOLA HEMORRHAGIC FEVER; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; PATHOPHYSIOLOGY; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELLS, CULTURED; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEIN BINDING; TOLL-LIKE RECEPTOR 4; VIRAL ENVELOPE PROTEINS;

EID: 85020202678     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006397     Document Type: Article

References (82)

1. CDC. 2014–2016 Ebola Outbreak in West Africa. 2016. Available from: https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html.
2. Martins KA, Jahrling PB, Bavari S, Kuhn JH, Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines. 2016:1–12.
3. Kilgore PE, Grabenstein JD, Salim AM, Rybak M, Treatment of ebola virus disease. Pharmacotherapy. 2015;35(1):43–53. doi: 10.1002/phar.1545 25630412
4. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB, Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest. 2000;80(2):171–86. 10701687
5. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW, Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol. 2004;17(3):390–400. doi: 10.1089/vim.2004.17.390 15357905
6. Ebihara H, Rockx B, Marzi A, Feldmann F, Haddock E, Brining D, et al. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis. 2011;204Suppl 3:S991–9. PubMed Central PMCID: PMCPMC3189992.
7. Fisher-Hoch SP, Platt GS, Lloyd G, Simpson DI, Neild GH, Barrett AJ, Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet. 1983;2(8358):1055–8. 6138602
8. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163(6):2371–82. doi: 10.1016/S0002-9440(10)63592-4 14633609
9. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK, Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 2011;13(11):930–6. doi: 10.1016/j.micinf.2011.05.002 21651988
10. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5(4):423–6. doi: 10.1038/7422 10202932
11. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP, Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system?Apoptosis. 2000;5(1):5–7. 11227491
12. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM, Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4(10):e837. Epub 2010/10/20. PubMed Central PMCID: PMC2950153. doi: 10.1371/journal.pntd.0000837 20957152
13. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol. 2004;78(19):10370–7. Epub 2004/09/16. PubMed Central PMCID: PMC516433. doi: 10.1128/JVI.78.19.10370-10377.2004 15367603
14. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol. 2003;163(6):2347–70. doi: 10.1016/S0002-9440(10)63591-2 14633608
15. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis. 2003;188(11):1630–8. doi: 10.1086/379199 14639532
16. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B, Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol. 2003;170(6):2797–801. 12626527
17. Lubaki NM, Ilinykh P, Pietzsch C, Tigabu B, Freiberg AN, Koup RA, et al. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. Journal of virology. 2013;87(13):7471–85. Epub 2013/04/26. PubMed Central PMCID: PMC3700277. doi: 10.1128/JVI.03316-12 23616668
18. Ilinykh PA, Lubaki NM, Widen SG, Renn LA, Theisen TC, Rabin RL, et al. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells. J Virol. 2015;89(15):7567–83. PubMed Central PMCID: PMCPMC4505630. doi: 10.1128/JVI.00924-15 25972536
19. Hensley LE, Young HA, Jahrling PB, Geisbert TW, Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett. 2002;80(3):169–79. 11803049
20. Gupta M, Spiropoulou C, Rollin PE, Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology. 2007;364(1):45–54. Epub 2007/03/30. doi: 10.1016/j.virol.2007.02.017 17391724
21. Yen B, Mulder LC, Martinez O, Basler CF, Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J Virol. 2014;88(21):12500–10. Epub 2014/08/22. PubMed Central PMCID: PMC4248944. doi: 10.1128/JVI.02163-14 25142601
22. Lubaki NM, Younan P, Santos RI, Meyer M, Iampietro M, Koup RA, et al. The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses. PLoS Pathog. 2016;12(12):e1006031. PubMed Central PMCID: PMCPMC5145241. doi: 10.1371/journal.ppat.1006031 27930745
23. Bray M, Geisbert TW, Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol. 2005;37(8):1560–6. doi: 10.1016/j.biocel.2005.02.018 15896665
24. Okumura A, Pitha PM, Yoshimura A, Harty RN, Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol. 2010;84(1):27–33. PubMed Central PMCID: PMCPMC2798428. doi: 10.1128/JVI.01462-09 19846529
25. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P, RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 2007;14(3):400–10. doi: 10.1038/sj.cdd.4402085 17301840
26. Takashiba S, Van Dyke TE, Amar S, Murayama Y, Soskolne AW, Shapira L, Differentiation of monocytes to macrophages primes cells for lipopolysaccharide stimulation via accumulation of cytoplasmic nuclear factor kappaB. Infect Immun. 1999;67(11):5573–8. PubMed Central PMCID: PMCPMC96928. 10531202
27. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS, Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 2007;56(1):45–50. doi: 10.1007/s00011-007-6115-5 17334670
28. Bray M, Mahanty S, Ebola hemorrhagic fever and septic shock. J Infect Dis. 2003;188(11):1613–7. doi: 10.1086/379727 14639530
29. Hellman J, Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis. PLoS Pathog. 2015;11(10):e1005088. doi: 10.1371/journal.ppat.1005088 26425845
30. Marcinkiewicz J, Bryniarski K, Nazimek K, Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention. Folia Med Cracov. 2014;54(3):39–48. 25694094
31. Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology. 2005;332(1):20–7. Epub 2005/01/22. doi: 10.1016/j.virol.2004.10.048 15661137
32. Bukreyev A, Marzi A, Feldmann F, Zhang L, Yang L, Ward JM, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology. 2009;383(2):348–61. Epub 2008/11/18. PubMed Central PMCID: PMC2649782. doi: 10.1016/j.virol.2008.09.030 19010509
33. Jones SM, Feldmann H, Ströher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–90. doi: 10.1038/nm1258 15937495
34. Reynolds JM, Martinez GJ, Chung Y, Dong C, Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci U S A. 2012;109(32):13064–9. PubMed Central PMCID: PMCPMC3420161. doi: 10.1073/pnas.1120585109 22826216
35. Escudero-Perez B, Volchkova VA, Dolnik O, Lawrence P, Volchkov VE, Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability. PLoS Pathog. 2014;10(11):e1004509. Epub 2014/11/21. PubMed Central PMCID: PMC4239094. doi: 10.1371/journal.ppat.1004509 25412102
36. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F, Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274(16):10689–92. 10196138
37. Medvedev AE, Vogel SN, Overexpression of CD14, TLR4, and MD-2 in HEK 293T cells does not prevent induction of in vitro endotoxin tolerance. J Endotoxin Res. 2003;9(1):60–4. doi: 10.1179/096805103125001360 12691621
38. Doehle BP, Hladik F, McNevin JP, McElrath MJ, Gale M, Jr.Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol. 2009;83(20):10395–405. PubMed Central PMCID: PMCPMC2753137. doi: 10.1128/JVI.00849-09 19706707
39. Zanin-Zhorov A, Tal-Lapidot G, Cahalon L, Cohen-Sfady M, Pevsner-Fischer M, Lider O, et al. Cutting edge: T cells respond to lipopolysaccharide innately via TLR4 signaling. J Immunol. 2007;179(1):41–4. 17579019
40. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282(5396):2085–8. 9851930
41. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol. 2006;80(5):2267–79. doi: 10.1128/JVI.80.5.2267-2279.2006 16474134
42. Akira S, Takeda K, Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511. doi: 10.1038/nri1391 15229469
43. Viatour P, Merville MP, Bours V, Chariot A, Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci. 2005;30(1):43–52. doi: 10.1016/j.tibs.2004.11.009 15653325
44. Brenner D, Blaser H, Mak TW, Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15(6):362–74. doi: 10.1038/nri3834 26008591
45. Gururaja TL, Yung S, Ding R, Huang J, Zhou X, McLaughlin J, et al. A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1. Chem Biol. 2007;14(10):1105–18. doi: 10.1016/j.chembiol.2007.08.012 17961823
46. Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, et al. Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol. 2013;87(7):3801–14. PubMed Central PMCID: PMCPMC3624207. doi: 10.1128/JVI.02695-12 23345511
47. Aldo PB, Craveiro V, Guller S, Mor G, Effect of culture conditions on the phenotype of THP-1 monocyte cell line. Am J Reprod Immunol. 2013;70(1):80–6. PubMed Central PMCID: PMCPMC3703650. doi: 10.1111/aji.12129 23621670
48. Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne RW, Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis. 2004;63(7):774–84. PubMed Central PMCID: PMCPMC1755048. doi: 10.1136/ard.2003.013029 15194571
49. Gupta M, Mahanty S, Ahmed R, Rollin PE, Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology. 2001;284(1):20–5. doi: 10.1006/viro.2001.0836 11352664
50. Yang YC, Hsu TY, Chen JY, Yang CS, Lin RH, Tumour necrosis factor-alpha-induced apoptosis in cord blood T lymphocytes: involvement of both tumour necrosis factor receptor types 1 and 2. Br J Haematol. 2001;115(2):435–41. 11703347
51. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R, C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. Journal of virology. 2002;76(13):6841–4. Epub 2002/06/07. PubMed Central PMCID: PMC136246. doi: 10.1128/JVI.76.13.6841-6844.2002 12050398
52. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology. 2003;305(1):115–23. Epub 2002/12/31. 12504546
53. Matsuno K, Nakayama E, Noyori O, Marzi A, Ebihara H, Irimura T, et al. C-type lectins do not act as functional receptors for filovirus entry into cells. Biochem Biophys Res Commun. 2010;403(1):144–8. PubMed Central PMCID: PMCPMC3393133. doi: 10.1016/j.bbrc.2010.10.136 21056544
54. Chan SY, Empig CJ, Welte FJ, Speck RF, Schmaljohn A, Kreisberg JF, et al. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell. 2001;106(1):117–26. Epub 2001/07/20. 11461707
55. Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol. 2006;80(20):10109–16. doi: 10.1128/JVI.01157-06 17005688
56. Rath PC, Aggarwal BB, TNF-induced signaling in apoptosis. J Clin Immunol. 1999;19(6):350–64. 10634209
57. Lin Y, Choksi S, Shen HM, Yang QF, Hur GM, Kim YS, et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem. 2004;279(11):10822–8. doi: 10.1074/jbc.M313141200 14701813
58. Harberts E, Fishelevich R, Liu J, Atamas SP, Gaspari AA, MyD88 mediates the decision to die by apoptosis or necroptosis after UV irradiation. Innate Immun. 2014;20(5):529–39. PubMed Central PMCID: PMCPMC4041851. doi: 10.1177/1753425913501706 24048771
59. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE, Cell death. N Engl J Med. 2009;361(16):1570–83. PubMed Central PMCID: PMCPMC3760419. doi: 10.1056/NEJMra0901217 19828534
60. McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015;112(15):4719–24. PubMed Central PMCID: PMCPMC4403189. doi: 10.1073/pnas.1502619112 25775592
61. Barber RC, Aragaki CC, Rivera-Chavez FA, Purdue GF, Hunt JL, Horton JW, TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet. 2004;41(11):808–13. PubMed Central PMCID: PMCPMC1383768. doi: 10.1136/jmg.2004.021600 15520404
62. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med. 1999;189(4):615–25. PubMed Central PMCID: PMCPMC2192941. 9989976
63. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497(7450):498–502. Epub 2013/05/03. PubMed Central PMCID: PMC3725830. doi: 10.1038/nature12118 23636320
64. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154–62. doi: 10.1001/jama.2013.2194 23512062
65. Younan P, Ramanathan P, Graber J, Gusovsky F, Bukreyev A, The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge. MBio. 2017;8(2). PubMed Central PMCID: PMCPMC5405229.
66. Geisbert TW, Jahrling PB, Exotic emerging viral diseases: progress and challenges. Nat Med. 2004;10(12 Suppl):S110–21. doi: 10.1038/nm1142 15577929
67. Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol. 2009;83(11):5890–903. PubMed Central PMCID: PMCPMC2681932. doi: 10.1128/JVI.01948-08 19297492
68. Merekoulias G, Alexopoulos EC, Belezos T, Panagiotopoulou E, Jelastopulu DM, Lymphocyte to monocyte ratio as a screening tool for influenza. PLoS Curr. 2010;2:RRN1154. PubMed Central PMCID: PMCPMC2847387. doi: 10.1371/currents.RRN1154 20383263
69. Cunha BA, McDermott BP, Mohan SS, Prognostic importance of lymphopenia in West Nile encephalitis. Am J Med. 2004;117(9):710–1. doi: 10.1016/j.amjmed.2004.05.023 15501215
70. Wyllie DH, Bowler IC, Peto TE, Relation between lymphopenia and bacteraemia in UK adults with medical emergencies. J Clin Pathol. 2004;57(9):950–5. PubMed Central PMCID: PMCPMC1770434. doi: 10.1136/jcp.2004.017335 15333656
71. Marzi A, Feldmann H, Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13(4):521–31. doi: 10.1586/14760584.2014.885841 24575870
72. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66. doi: 10.1016/S0140-6736(15)61117-5 26248676
73. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15(10):1156–66. doi: 10.1016/S1473-3099(15)00154-1 26248510
74. Durbin A, Hall S, Siew J, Whitehead S, Collins P, Murphy B, Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology. 1997;235(2):232–32.
75. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A. 2003;100(26):15889–94. doi: 10.1073/pnas.2237038100 14673108
76. Hanggi K, Vasilikos L, Valls AF, Yerbes R, Knop J, Spilgies LM, et al. RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function. Cell Death Dis. 2017;8(2):e2588. doi: 10.1038/cddis.2017.20 28151480
77. Langmead B, Salzberg SL, Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–9. PubMed Central PMCID: PMCPMC3322381. doi: 10.1038/nmeth.1923 22388286
78. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21. PubMed Central PMCID: PMCPMC3530905. doi: 10.1093/bioinformatics/bts635 23104886
79. Anders S, Pyl PT, Huber W, HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166–9. PubMed Central PMCID: PMCPMC4287950. doi: 10.1093/bioinformatics/btu638 25260700
80. Robinson MD, McCarthy DJ, Smyth GK, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40. PubMed Central PMCID: PMCPMC2796818. doi: 10.1093/bioinformatics/btp616 19910308
81. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, et al. AmiGO: online access to ontology and annotation data. Bioinformatics. 2009;25(2):288–9. PubMed Central PMCID: PMCPMC2639003. doi: 10.1093/bioinformatics/btn615 19033274
82. Gene Ontology C, Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015;43(Database issue):D1049–56. PubMed Central PMCID: PMCPMC4383973. doi: 10.1093/nar/gku1179 25428369